KDR Biotech markets DASGIP Parallel Bioreactor Systems in Korea

19-Jun-2009 - Germany

DASGIP AG and KDR Biotech have signed a cooperation agreement. Thus, KDR Biotech will hold the exclusive distribution of DASGIP Parallel Bioreactor Systems on the Korean market. First sales are already initiated.

Chung, Youn-Taek, Managing Director of KDR Biotech, appreciates the partnership with DASGIP. “By including the DASGIP products into our portfolio we are aiming at winning first class labs in the areas of screening, strain and cell line development as well as process development as new customers”, states Chung, Youn-Taek.

Since 2007 DASGIP has been working on its expansion towards the Asian market. CEO Thomas Drescher points out: “With SCRUM, Tokyo, and Quintech, Singapore, we already are well represented in Japan and Singapore. Now we are happy to have found a reliable partner to enter the Korean market as well”.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy